珠江学者特聘教授、广州市高层次人才(优秀专家)、人社部高层留学人才(
2019
),医学免疫
学专业广州医科大学南山优秀人才,呼吸疾病国家重点实验室 PI,教授,博导。
一直从事呼吸道病毒感染免疫研究,在澳大利亚墨尔本大学诺贝尔奖得主
Peter Doherty
实验室学
习和工作 6 年,在 T 细胞抗新发传染病病毒感染相关研究领域取得国际领先成果。先后阐述了 H7N9
引起的细胞因子风暴(
PNAS 2014
,
IF=12.8
),
H7N9
感染康复需要多种细胞免疫机制共同作用(
Nature
communications 2015,IF=17.7),及 H7N9 急性感染可能会引起部分 T 细胞衰竭(Nature communications
2018
,
IF=17.7
)。新冠爆发后,发现了在一定的中和抗体水平下,
T
细胞免疫对重症
COVID-19
病人
康复至关重要(Am J Respir Crit Care Med 2020,IF=30.5),核酸和抗体均为阴性的密切接触者体内产
生新冠病毒特异性 T 细胞反应,阐述了新冠暴露会产生连续感染谱,提示人们对“病毒感染”需要重
新定义,(
Nature communications 2021
,
IF=17.7
)
,
发现病毒特异性
CD4+
反应强度对新冠病毒中和抗
体的长期维持具有重要作用(
Signal Transduction and Targeted Therapy,2022,IF=38.1
)。在两针灭活疫
苗的基础上,验证了第三针亚单位疫苗加强相比同源加强显著提高了针对 SARS-CoV-2 中和抗体产生,
该中和抗体对多种变异株如 Omicron 均有很好的交叉反应性(Emerging Microbes & Infections 2022,
IF=19.5
)。在两针灭活的基础上,研究了国产
mRNA
一代苗序贯加强的免疫原性反应及对变异株的
保护(Cell Research,共一第三,IF=46.3)。
共发表
SCI
论文
42
篇,以第一作者或通讯作者
SCI
论文累计影响因子
226.5
,共计
20
篇,其中
IF>10 分以上 9 篇。
1. LIU X, LI Y, WANG Z, et al. Safety and superior immunogenicity of heterologous boosting with an
RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults [J]. Cell Res, 2022, 32(8): 777-80.
2. WANG Z, YANG X, MEI X, et al. SARS-CoV-2-specific CD4(+) T cells are associated with
long-term persistence of neutralizing antibodies [J]. Signal Transduct Target Ther, 2022, 7(1): 132.
3. ZHONG J, LIU S, CUI T, et al. Heterologous booster with inhaled Adenovirus vector COVID-19
vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants [J]. Emerg Microbes
Infect, 2022: 1-18
4. ZHAO Z, CUI T, Huang M, et al. Heterologous boosting with third dose of coronavirus disease
recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe
acute respiratory syndrome coronavirus 2 variants [J]. Emerg Microbes Infect, 2022, 11(1): 829-40.
5. WANG Z, YANG X, ZHONG J, et al. Exposure to SARS-CoV-2 generates T-cell memory in the
absence of a detectable viral infection [J]. Nat Commun, 2021, 12(1): 1724.
6. WANG Z, YANG X, ZHOU Y, et al. COVID-19 Severity Correlates with Weaker T-Cell Immunity,
Hypercytokinemia, and Lung Epithelium Injury [J]. Am J Respir Crit Care Med, 2020, 202(4): 606-10.
7. WANG Z, ZHU L, NGUYEN T H O, et al. Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells
persist during fatal H7N9 disease [J]. Nat Commun, 2018, 9(1): 824.
8. WANG Z, WAN Y, QIU C, et al. Recovery from severe H7N9 disease is associated with diverse
response mechanisms dominated by CD8(+) T cells [J]. Nat Commun, 2015, 6: 6833.
9. JIA X, CHUA B Y, LOH L, et al. High expression of CD38 and MHC class II on CD8(+) T cells
during severe influenza disease reflects bystander activation and trogocytosis [J]. Clin Transl Immunology,
2021, 10(9): e1336.
10. WANG Z, ZHANG A, WAN Y, et al. 2014. Early hypercytokinemia is associated with
interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection[J].
Proceedings of the National Academy of Sciences of the United States of America 111:769-774.
代表性成果: